$25.07
Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Overview
52-week range
$14
$35
51% of range
Avg surprise (last 2)
-28.6%
Avg reaction (last 1)
+3.7%
100% positive
Latest IV / EM
94%
EM ±14.7% · $25 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | — | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | — | $-0.02 | +100.0% | — | +3.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.08 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.54 | $-0.21 | -157.1% | — | — | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-3.57 | — | — | — | — | financials |
| Mon Sep 30, 2024 | Sep 2024 | $-2.59 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.54 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $264M | $216M | — | $217M | $181M | $121M | — | $102M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $27M | $5M | — | $33M | $-18M | $-58M | — | $-61M |
| Net income | $-637,000 | $-510,000 | — | $24M | $-72M | $-103M | — | $-68M |
| EPS (diluted) | — | — | — | $0.08 | $-7.97 | $-3.57 | — | $-2.59 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $820M | — | $753M | $719M | $31M | $64M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.06B | $1.01B | $998M | $854M | $833M | — | $216M | — |
| Total assets | $1.23B | $1.16B | $1.13B | $985M | $955M | — | $344M | — |
| Long-term debt | $393M | $381M | $379M | $376M | $374M | — | $319M | — |
| Total liabilities | $638M | $569M | $548M | $506M | $502M | — | $621M | — |
| Total equity | $592M | $593M | $577M | $478M | $453M | $-2.60B | $-2.50B | $-2.44B |